Livzon Pharmaceutical Group Inc. (SHE:000513)

Market Cap	28.03B -5.9%
Revenue (ttm)	11.85B -0.1%
Net Income	2.14B +5.8%
EPS	2.38 +8.9%
Shares Out	887.91M
PE Ratio	14.48
Forward PE	13.52
Dividend	1.10 (3.15%)
Ex-Dividend Date	Jun 13, 2025

Volume	763,000
Average Volume	8,215,739
Open	35.35
Previous Close	34.54
Day's Range	34.60 - 35.35
52-Week Range	32.94 - 44.87
Beta	0.35
RSI	36.12
Earnings Date	Mar 25, 2026

About SHE:000513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate and perospirone hydrochloride...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 9,067
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000513

Financial Performance

In 2024, SHE:000513's revenue was 11.81 billion, a decrease of -4.97% compared to the previous year's 12.43 billion. Earnings were 2.06 billion, an increase of 5.50%.